TECH - Bio-Techne Corporation
196.75 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 195.65 |
| Open | 195.32 |
| Bid | 140.23 x 1000 |
| Ask | 197.10 x 800 |
| Day's Range | 194.51 - 196.99 |
| 52 Week Range | 132.75 - 206.04 |
| Volume | 71,959 |
| Avg. Volume | 219,005 |
| Market Cap | 7.43B |
| Beta (3Y Monthly) | 1.57 |
| PE Ratio (TTM) | 78.83 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.28 (0.66%) |
| Ex-Dividend Date | 2019-02-14 |
| 1y Target Est | N/A |
- PR Newswire•13 days ago
Bio-Techne Scores A Trio Of CiteAb 2019 Awards
MINNEAPOLIS , March 5, 2019 /PRNewswire/ -- Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, was honored ...
- PR Newswire•13 days ago
Bio-Techne To Present At The Barclays Global Healthcare Conference
MINNEAPOLIS , March 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel , Chief Financial Officer will present at the Barclays Global Healthcare Conference on Wednesday, ...
- GlobeNewswire•15 days ago
Report: Exploring Fundamental Drivers Behind Stericycle, B&G Foods, QTS Realty Trust, Trimble, Electronics for Imaging, and Bio-Techne — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•20 days ago
Bio-Techne Signs Strategic Cooperation Agreement with Lisen Imprinting Diagnostics
MINNEAPOLIS, Feb. 26, 2019 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement in the precision medicine field with Lisen Imprinting Diagnostics Wuxi Co., Ltd, China. Liwen Pei, Managing Director of Bio-Techne China, and Ning Zhou, CEO of Lisen, attended the meeting and signing ceremony. Bio-Techne is a leading provider of high-quality consumables and instruments for the life science and molecular diagnostic markets.
- PR Newswire•26 days ago
Bio-Techne To Present At The 8th Annual SVB Leerink Global Healthcare Conference
MINNEAPOLIS , Feb. 20, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer will present at the 8 th Annual SVB Leerink Global ...
- PR Newswire•last month
Bio-Techne Releases Second Quarter Fiscal 2019 Results
MINNEAPOLIS , Feb. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ended December 31, 2018 . Second Quarter FY2019 Snapshot Second ...
- PR Newswire•last month
Bio-Techne Declares Dividend
MINNEAPOLIS , Feb. 5, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, ...
- PR Newswire•2 months ago
ExoDx® Prostate(IntelliScore) (EPI) Recommended in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
MINNEAPOLIS, Jan. 31, 2019 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced the National Comprehensive Cancer Network (NCCN) decision to include EPI as a recommended test in their Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection (Version 1.2019). The updated treatment algorithm includes EPI testing prior to a first prostate biopsy or after a negative biopsy to assist patients and urologists in further defining the probability of high-grade cancer and in reaching a joint decision to either proceed with a prostate biopsy or continue monitoring.
- PR Newswire•2 months ago
Bio-Techne Introduces 48-Digoxigenin Cartridge for the Ella Platform
MINNEAPOLIS , Jan. 29, 2019 /PRNewswire/ -- Bio-Techne today announced the launch of a new customizable cartridge format for their ProteinSimple-branded Ella™ immunoassay platform. Ella allows users to ...
- PR Newswire•2 months ago
Bio-Techne Introduces CE-SDS PLUS for Maurice™ System
MINNEAPOLIS , Jan. 28, 2019 /PRNewswire/ -- Bio-Techne today announced the launch of the CE-SDS PLUS system for its ProteinSimple-branded Maurice ™ platform. This new system further expands the usability ...
- PR Newswire•2 months ago
Bio-Techne Launches Cell and Gene Therapy Portfolio
MINNEAPOLIS , Jan. 24, 2019 /PRNewswire/ -- Bio-Techne announces the launch of their cell and gene therapy portfolio. As a leading manufacturer of GMP-grade ancillary materials and automated instrumentation, ...
- PR Newswire•2 months ago
Bio-Techne To Host Conference Call On February 5, 2019, To Announce Second Quarter 2019 Financial Results
MINNEAPOLIS , Jan. 16, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, February 5, 2019 , at 8:00 a.m. CST to review second ...
- PR Newswire•3 months ago
Bio-Techne To Present At The 37th Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS , Dec. 20, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer will present at the 37 th Annual J.P. Morgan ...
- PR Newswire•3 months ago
Bio-Techne Releases GMP ROCK Inhibitor and CHIR 99021 for Stem Cell Therapy
MINNEAPOLIS , Dec. 4, 2018 /PRNewswire/ -- Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used ...
- PR Newswire•4 months ago
Bio-Techne To Present At The Citi 2018 Global Healthcare Conference
MINNEAPOLIS , Nov. 20, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Dave Eansor , President Protein Sciences will present at the Citi 2018 Global Healthcare Conference ...
- GlobeNewswire•5 months ago
Report: Exploring Fundamental Drivers Behind Equity Lifestyle Properties, AvalonBay Communities, Kadant, Mastercard, Bio-Techne, and Erie Indemnity — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•5 months ago
Bio-Techne Releases First Quarter Fiscal 2019 Results
MINNEAPOLIS , Oct. 30, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the first quarter ended September 30, 2018 . First Quarter FY2019 Snapshot First ...
- PR Newswire•5 months ago
Bio-Techne To Present At The 2018 Stephens NY Investment Conference
MINNEAPOLIS , Oct. 26, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the 2018 Stephens NY Investment ...
- PR Newswire•5 months ago
Bio-Techne Signs Strategic Cooperation Agreement with Micropoint Bioscience
MINNEAPOLIS, Oct. 12, 2018 /PRNewswire/ -- Bio-Techne has entered into a strategic cooperation agreement with Micropoint Bioscience of Shenzhen, China. Chuck Kummeth, President and CEO of Bio-Techne, Yan Pingyi, Chairman of Micropoint Bioscience, and Wang Bin, Executive Vice President, Shenzhen Association of Medical Devices, all attended the meeting and signing ceremony. Micropoint Bioscience is a high-tech, newly-listed enterprise in China that has developed a microfluidic diagnostic chip for point-of-care (POC) testing.
- PR Newswire•5 months ago
Bio-Techne To Host Conference Call On October 30, 2018 To Announce First Quarter 2019 Financial Results
MINNEAPOLIS , Oct. 11, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call on Tuesday, October 30, 2018 at 8:00 a.m. CDT to review first ...
- PR Newswire•5 months ago
Bio-Techne Scientist Presented with the CASSS CE Pharm Award
MINNEAPOLIS , Oct. 2, 2018 /PRNewswire/ -- Bio-Techne is proud to announce that one of its Principal Scientists, Jiaqi Wu , Ph.D., was presented with the CE Pharm Award at this year's CE Pharm meeting ...
- PR Newswire•6 months ago
Bio-Techne Announces Cell and Gene Therapy Initiative
MINNEAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Bio-Techne, a global leader of research and manufacturing-grade reagents, has announced a corporate initiative to advance cell and gene therapy research and ex vivo cell processing. Through strategic acquisitions and internal scientific innovation, Bio-Techne has become uniquely positioned to provide a comprehensive, innovative, and flexible set of reagents and instrumentation across the cell and gene therapy workflow. Bio-Techne's solutions for the cell therapy workflow span its portfolio, including GMP-grade cytokines and growth factors, high-quality antibodies for flow cytometry and immunocytochemical characterization, gold-standard immunoassays and next-generation automated immunoassay platforms, DNA and RNA in situ hybridization (ISH) assays, GMP-grade small molecules, and more.
- PR Newswire•6 months ago
Bio-Techne Supports International Antibody Validation Meetings
MINNEAPOLIS, Sept. 19, 2018 /PRNewswire/ -- Bio-Techne is proud to be sharing its 30+ years of industry leading expertise in antibody development and validation from its R&D Systems and Novus Biologicals brands at the 3rd International Antibody Validation Meeting on September 20-21, 2018. Leading researchers from academia, the biopharma industry, and antibody developers will gather to discuss best practices in research antibody validation with the goal of improving validation standards and enhancing research reproducibility. Birte Aggeler, Ph.D., Director of Antibody Development and Flow Cytometry at Bio-Techne, will present results from Bio-Techne's newest approaches to antibody validation, including the company's initiative to use CRISPR gene editing technology to validate antibodies in knockout (KO) cell lines.
- PR Newswire•6 months ago
Bio-Techne Announces Publication of Data Demonstrating Additional Clinical Validation of its EPI Test in European Urology Journal
MINNEAPOLIS , Sept. 18, 2018 /PRNewswire/ -- Bio-Techne today announced the online publication of its second prospective US clinical validation study of the Exosome Diagnostics-branded ExoDx® Prostate(IntelliScore) ...